Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

• Status: Unknown status
• Trial end date: 2017-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating such patients. The primary endpoint is to compare the recurrence-free survival after 1-year or 2-year treatment with icotinib.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Betta Pharmaceuticals Co., Ltd.; Betta Pharmaceuticals Co.,Ltd.

Criteria

Inclusion Criteria:

• The patients signed the written informed consent

• The patients present with operable stage II-IIIA non-small-cell lung cancers with 19 or 21 exon mutation

• The patients have no history of anti-cancer therapies including chemotherapy, radiation therapy

• The patients' Eastern Cooperative Oncology Group scores are ≤ 0-2

Exclusion Criteria:

• Patients with unresected tumor

• Wild EGFR type

• Allergic to the study drug

• Patients have severe non-cancerous diseases

• Patients are undergoing current administration of anti-cancer therapies, or are attending some other clinical trials